LLY

750.76

-1.27%↓

NVO

124.54

-0.75%↓

UNH

438.96

-0.71%↓

JNJ

147.47

-0.91%↓

MRK

125.56

-0.63%↓

LLY

750.76

-1.27%↓

NVO

124.54

-0.75%↓

UNH

438.96

-0.71%↓

JNJ

147.47

-0.91%↓

MRK

125.56

-0.63%↓

LLY

750.76

-1.27%↓

NVO

124.54

-0.75%↓

UNH

438.96

-0.71%↓

JNJ

147.47

-0.91%↓

MRK

125.56

-0.63%↓

LLY

750.76

-1.27%↓

NVO

124.54

-0.75%↓

UNH

438.96

-0.71%↓

JNJ

147.47

-0.91%↓

MRK

125.56

-0.63%↓

LLY

750.76

-1.27%↓

NVO

124.54

-0.75%↓

UNH

438.96

-0.71%↓

JNJ

147.47

-0.91%↓

MRK

125.56

-0.63%↓

HomeStock ListBluebird Bio Inc

Bluebird Bio Inc

Closed

1.1 -5.17

Overview

Share price change

24h

Current

Min

1.07

Max

1.18

Key metrics

By Trading Economics

Income

1.2M

-72M

Sales

5.5M

12M

EPS

-0.66

Profit margin

-578.849

EBITDA

670K

-84M

Recommendations

By TipRanks

Rating Consensus

Neutral

12 Months Forecast

+216.38 upside

Dividends

By Dow Jones

Next earnings

7 May 2024

Market Stats

By TradingEconomics

Market Cap

-1.9M

234M

Previous open

6.27

Previous close

1.1

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

Bluebird Bio Inc chart

Related News

8 Dec 2023, 20:56 UTC

Major Market Movers

Bluebird Bio Shares Slide 41% on Black-Box Label, Higher Price for Sickle-Cell Treatment

8 Dec 2023, 18:45 UTC

Top News

FDA Approves World's First Crispr Gene-Editing Drug for Sickle-Cell Disease -- 2nd Update

8 Dec 2023, 16:45 UTC

Top News

FDA Approves World's First Crispr Gene-Editing Drug for Sickle-Cell Disease -- Update

24 Nov 2023, 12:00 UTC

Top News

Gene Editing Will Change Medicine -- and Maybe Health Investing Too -- Heard on the Street -- WSJ

Peer Comparison

Price change

Bluebird Bio Inc forecast

Price Target

By TipRanks

216.38% upside

12 Months Forecast

Average 3.67 USD  216.38%

High 8 USD

Low 1 USD

Based on 11 Wall Street analysts offering 12 month price targets for Bluebird Bio Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

11 ratings

4

Buy

5

Hold

2

Sell

Technical Score

By Trading Central

N/A / 1.16 Support&Resistance

Short Team

Strong Bearish Evidence

Intermediate Term

Weak Bearish Evidence

Long Term

Weak Bearish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

EBITDA

Operating profit

$

About Bluebird Bio Inc

bluebird bio, Inc. is a biotechnology company. The Company focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases and cancer. It develops LentiGlobin for sickle cell disease (SCD) as a one-time treatment for patients with SCD, a hereditary blood disorder resulting from a mutation in the ß-globin gene that causes polymerization of hemoglobin proteins, resulting in abnormal red blood cell function. It builds an integrated product platform with therapeutic in a variety of indications based on its lentiviral gene addition platform, gene editing and cancer immunotherapy capabilities. Its programs in genetic disease include betibeglogene autotemcel; LentiGlobin gene therapy for sickle cell disease (SCD); and elivaldogene autotemcel. Its programs in oncology are focused on developing novel T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies.